Literature DB >> 25753730

RNA-targeted Therapeutics for ALS.

Linga V Reddy1, Timothy M Miller.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease leading to cell death of predominantly motor neurons. Despite extensive research in this disease, finding a way to slow the progress of the disease has been challenging. RNA-targeted therapeutic approaches, including small interfering RNA and antisense oligonucleotides are being developed for genetic forms of ALS. ALS provides an unique opportunity for the use of RNA inhibition strategies given a well-defined animal model, extensive available information regarding the causative genes, and recent experience in phase 1 clinical trial.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25753730      PMCID: PMC4404448          DOI: 10.1007/s13311-015-0344-z

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  43 in total

Review 1.  Strategies for silencing human disease using RNA interference.

Authors:  Daniel H Kim; John J Rossi
Journal:  Nat Rev Genet       Date:  2007-03       Impact factor: 53.242

2.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

3.  An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.

Authors:  Timothy M Miller; Alan Pestronk; William David; Jeffrey Rothstein; Ericka Simpson; Stanley H Appel; Patricia L Andres; Katy Mahoney; Peggy Allred; Katie Alexander; Lyle W Ostrow; David Schoenfeld; Eric A Macklin; Daniel A Norris; Georgios Manousakis; Matthew Crisp; Richard Smith; C Frank Bennett; Kathie M Bishop; Merit E Cudkowicz
Journal:  Lancet Neurol       Date:  2013-03-29       Impact factor: 44.182

4.  Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

Authors:  Cédric Raoul; Toufik Abbas-Terki; Jean-Charles Bensadoun; Sandrine Guillot; Georg Haase; Jolanta Szulc; Christopher E Henderson; Patrick Aebischer
Journal:  Nat Med       Date:  2005-03-13       Impact factor: 53.440

5.  Antisense reduction of tau in adult mice protects against seizures.

Authors:  Sarah L DeVos; Dustin K Goncharoff; Guo Chen; Carey S Kebodeaux; Kaoru Yamada; Floy R Stewart; Dorothy R Schuler; Susan E Maloney; David F Wozniak; Frank Rigo; C Frank Bennett; John R Cirrito; David M Holtzman; Timothy M Miller
Journal:  J Neurosci       Date:  2013-07-31       Impact factor: 6.167

6.  Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice.

Authors:  Oleg Butovsky; Mark P Jedrychowski; Ron Cialic; Susanne Krasemann; Gopal Murugaiyan; Zain Fanek; David J Greco; Pauline M Wu; Camille E Doykan; Olga Kiner; Robert J Lawson; Matthew P Frosch; Nathalie Pochet; Rachid El Fatimy; Anna M Krichevsky; Steven P Gygi; Hans Lassmann; James Berry; Merit E Cudkowicz; Howard L Weiner
Journal:  Ann Neurol       Date:  2014-11-27       Impact factor: 10.422

7.  Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice.

Authors:  Erica D Koval; Carey Shaner; Peter Zhang; Xavier du Maine; Kimberlee Fischer; Jia Tay; B Nelson Chau; Gregory F Wu; Timothy M Miller
Journal:  Hum Mol Genet       Date:  2013-06-04       Impact factor: 6.150

8.  An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1.

Authors:  Stefania Guareschi; Emanuela Cova; Cristina Cereda; Mauro Ceroni; Elena Donetti; Daryl A Bosco; Davide Trotti; Piera Pasinelli
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-13       Impact factor: 11.205

9.  Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1.

Authors:  Sarah Pickles; Laurie Destroismaisons; Sarah L Peyrard; Sarah Cadot; Guy A Rouleau; Robert H Brown; Jean-Pierre Julien; Nathalie Arbour; Christine Vande Velde
Journal:  Hum Mol Genet       Date:  2013-06-04       Impact factor: 6.150

Review 10.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides.

Authors:  Ryszard Kole; Adrian R Krainer; Sidney Altman
Journal:  Nat Rev Drug Discov       Date:  2012-01-20       Impact factor: 84.694

View more
  6 in total

Review 1.  Disease Mechanisms of C9ORF72 Repeat Expansions.

Authors:  Tania F Gendron; Leonard Petrucelli
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody.

Authors:  Sarah Cantor; Wei Zhang; Nicolas Delestrée; Leonor Remédio; George Z Mentis; Steven J Burden
Journal:  Elife       Date:  2018-02-20       Impact factor: 8.140

Review 3.  Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis.

Authors:  G Y Wang; S L Rayner; R Chung; B Y Shi; X J Liang
Journal:  Mater Today Bio       Date:  2020-05-04

4.  Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis.

Authors:  Karen K Ling; Michaela Jackson; Duah Alkam; Dawei Liu; Norm Allaire; Chao Sun; Mahmoud Kiaei; Alexander McCampbell; Frank Rigo
Journal:  Neurobiol Dis       Date:  2018-03-06       Impact factor: 5.996

Review 5.  RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis.

Authors:  Stéphane Mathis; Gwendal Le Masson
Journal:  Biomedicines       Date:  2018-01-15

Review 6.  Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.

Authors:  Ashok Verma
Journal:  Ann Indian Acad Neurol       Date:  2018 Jan-Mar       Impact factor: 1.383

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.